Research Horizons


NEJM: Emapalumab Clinical Trial Shows Positive Results Against HLH

“For the first time we have a truly targeted way to treat HLH and a drug with very low toxicity.”

—Michael Jordan, MD

Clinical trial results published in the New England Journal of Medicine show that using emapalumab to treat patients with hemophagocytic lymphohistiocytosis (HLH) saved lives with less toxicity and fewer side effects.

The results represent a significant achievement in a 20-year journey to battle HLH. This study suggests that emapalumab—the first drug ever approved for HLH by the U.S. Food and Drug Administration—when  administered with dexamethasone should become the standard of care for ‘second line’ treatment of HLH, Jordan says.

Read the Cincinnati Children’s announcement
Publication Information
Original title: Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis
Published in: New England Journal of Medicine
Publish date: May 6, 2020
Read the Study

Research By

Michael Jordan, MD
Division of Bone Marrow Transplantation and Immune Deficiency
Dr. Jordan's research includes seeks a better understanding of histiocytic disorders and to develop novel therapies for them.